Sign in to view content

Baseline Factors Associated With 1-Year Outcomes in Phase III Comparison of SB11 (Approved Ranibizumab Biosimilar) With Reference Ranibizumab in nAMD

Neil M. Bressler, MD

Video
Published 2022

Related

Primary Analysis Results of the Phase 3 Archway Trial of the Port Delivery System With Ranibizumab (PDS) for Patients With Neovascular AMD
Peter A. Campochiaro, MD
Annual Meeting Talks
2020
A Phase 2 Safety and Efficacy Trial of AU-011, a Virus-Like Drug Conjugate, With Dose Escalation and Randomized Masked Expansion in Uveal Melanoma
Prithvi Mruthyunjaya, MD, MHS
Updates from the Field
2021
Unsupervised Deep Learning for Grading Age-Related Macular Degeneration Using Retinal Fundus Images
Neesurg S Mehta, MD
On Demand Cases, Courses, and Papers
2021

Category: AMD-Neovascular

See more